Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
To view or add a comment, sign in GLP-1 based therapies are rapidly evolving beyond diabetes and obesity
Scores on the Three-Factor Eating Questionnaire (TFEQ-R18) improved in all treatment groups, with Cagrilintide producing greater improvements than placebo in specific domains: cognitive restraint, notably at 1.2 mg and 4.5 mg, emotional eating notably at 0.3 mg and 2.4 mg, and uncontrolled eating notably at 1.24.5 mg
Slows down collagen breakdown and improves elasticity
Analyses of human insulitis lesions have suggested that signals released from stressed -cells precedes, and putatively initiates, the development of insulitis (31)
doi:10.1016/j.biopsych.2011.10.024